A phase 3 study published in The Lancet in 2026 found that oral semaglutide was not effective in slowing clinical progression for participants with early-stage Alzheimer’s disease. The multicenter trial involved 3,808 participants across 40 countries, according to reporting from NHI.no.
Results of the Oral Semaglutide Phase 3 Trial
A multicenter, randomized, placebo-controlled phase 3 study published in The Lancet evaluated the efficacy and safety of oral semaglutide for patients with early Alzheimer’s disease. According to NHI.no, the research took place across 566 sites in 40 different countries.
The study focused on participants between 55 and 85 years old who had amyloid-confirmed Alzheimer’s disease, specifically those presenting with mild dementia or mild cognitive impairment. A total of 3,808 participants were randomized to receive either a placebo or oral semaglutide at a flexible dose of up to 14 mg once daily.
The participants had an average age of 72 years and were observed for a period of up to 156 weeks. The results indicated that oral semaglutide did not effectively slow the clinical progression of the disease in these participants. NHI.no reported that the safety and tolerance of the drug in this patient group were consistent with its performance in other medical indications.
GLP-1 Agonists and Dementia Risk
The investigation into semaglutide stems from broader evidence regarding GLP-1 receptor agonists. According to NHI.no, data from animal models, clinical trials, and real-world studies involving individuals with obesity and/or type 2 diabetes suggested a reduced risk of Alzheimer’s disease and dementia following exposure to these medications.
The biological basis for this research involves the pathophysiology of Alzheimer’s. NHI.no notes that neuroimmune dysfunction and neuroinflammation are identified as key factors in the disease, appearing during the early stages. Research on mice indicated that GLP-1 receptor agonists influence various metabolic, vascular, and inflammatory processes involved in how Alzheimer’s develops.
While observational and real-world studies showed a reduced risk of all-cause disease and Alzheimer’s for patients with obesity and type 2 diabetes treated with GLP-1 receptor agonists, the phase 3 trial for early-stage symptomatic Alzheimer’s did not replicate these benefits in slowing clinical progression.
Clinical Parameters of the EVOKE Research
Parallel to the reported results, Ahus has detailed the structure of the EVOKE study, which examines everyday function and higher brain functions, such as cognition, in people with early-stage Alzheimer’s.
- Duration: The study lasts 173 weeks, totaling three years and four months.
- Medical Monitoring: Participants are required to attend 17 doctor visits and one telephone consultation.
- Testing Protocols: Study visits include head imaging and cognitive tests. Blood samples are collected during 10 of these visits.
- Methodology: Participants are randomly assigned to receive either semaglutide or a placebo tablet containing no active study medicine. The assignment remains unknown until the study concludes.
The EVOKE study aims to determine if the medication affects the progression of cognitive and functional decline. Potential drawbacks for participants noted by Ahus include the possibility of side effects, the potential for the medicine to have no effect on symptoms, and a higher demand for time and attention compared to standard treatment.
Consult your healthcare provider for medical advice or treatment options regarding Alzheimer’s disease.
